These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 26826204)

  • 1. Increased CSF neurogranin concentration is specific to Alzheimer disease.
    Wellington H; Paterson RW; Portelius E; Törnqvist U; Magdalinou N; Fox NC; Blennow K; Schott JM; Zetterberg H
    Neurology; 2016 Mar; 86(9):829-35. PubMed ID: 26826204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
    Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.
    Lista S; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Nisticò R; Floris R; Garaci F; Hampel H;
    J Alzheimers Dis; 2017; 59(4):1327-1334. PubMed ID: 28731449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
    Kvartsberg H; Duits FH; Ingelsson M; Andreasen N; Öhrfelt A; Andersson K; Brinkmalm G; Lannfelt L; Minthon L; Hansson O; Andreasson U; Teunissen CE; Scheltens P; Van der Flier WM; Zetterberg H; Portelius E; Blennow K
    Alzheimers Dement; 2015 Oct; 11(10):1180-90. PubMed ID: 25533203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
    Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
    Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia.
    Willemse EAJ; Sieben A; Somers C; Vermeiren Y; De Roeck N; Timmers M; Van Broeckhoven C; De Vil B; Cras P; De Deyn PP; Martin JJ; Teunissen CE; Engelborghs S; Bjerke M
    Neurobiol Aging; 2021 Dec; 108():99-109. PubMed ID: 34551375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer's disease.
    Xue M; Sun FR; Ou YN; Shen XN; Li HQ; Huang YY; Dong Q; Tan L; Yu JT;
    Aging (Albany NY); 2020 May; 12(10):9365-9379. PubMed ID: 32421689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.
    Portelius E; Olsson B; Höglund K; Cullen NC; Kvartsberg H; Andreasson U; Zetterberg H; Sandelius Å; Shaw LM; Lee VMY; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk DA; McCluskey L; Elman L; McBride J; Toledo JB; Trojanowski JQ; Blennow K
    Acta Neuropathol; 2018 Sep; 136(3):363-376. PubMed ID: 29700597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.
    Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F
    J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias.
    Hanes J; Kovac A; Kvartsberg H; Kontsekova E; Fialova L; Katina S; Kovacech B; Stevens E; Hort J; Vyhnalek M; Boonkamp L; Novak M; Zetterberg H; Hansson O; Scheltens P; Blennow K; Teunissen CE; Zilka N
    Neurology; 2020 Dec; 95(22):e3026-e3035. PubMed ID: 32973122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurogranin as a Novel Biomarker in Alzheimer's Disease.
    Agnello L; Gambino CM; Lo Sasso B; Bivona G; Milano S; Ciaccio AM; Piccoli T; La Bella V; Ciaccio M
    Lab Med; 2021 Mar; 52(2):188-196. PubMed ID: 32926148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease.
    Tible M; Sandelius Å; Höglund K; Brinkmalm A; Cognat E; Dumurgier J; Zetterberg H; Hugon J; Paquet C; Blennow K
    Neurology; 2020 Aug; 95(8):e953-e961. PubMed ID: 32586895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium.
    Halaas NB; Zetterberg H; Idland AV; Knapskog AB; Watne LO; Blennow K
    J Alzheimers Dis; 2021; 81(2):667-677. PubMed ID: 33814433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders.
    Yilmaz A; Fuchs D; Price RW; Spudich S; Blennow K; Zetterberg H; Gisslén M
    Curr HIV/AIDS Rep; 2019 Feb; 16(1):76-81. PubMed ID: 30649659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.